Guidelines Panel Meeting: Salvage Therapy for Prostate Cancer (2023)

January 1, 2023 to April 18, 2023

Panel members will be reviewing evidence prepared and presented by a methodologist who has been extracting and analyzing data from research articles. The panelists will inquire about aspects of the evidence and the methodologists will provide explanations. The panel will discuss the evidence and deliberate on the best practice methods of salvage therapy for prostate cancer.

Target Audience

This activity is limited to Salvage Therapy for Prostate Cancer Guidelines Panel Members only. 

Learning Objectives

After completing this activity, participants will be able to:

  1. Analyze the latest scientific evidence for early detection of prostate cancer.
  2. Recommend appropriate screening methods for detecting prostate cancer at an early stage.
  3. Apply improved critical thinking skills to medical literature reviews.
Course summary
Available credit: 
  • 12.00 AMA PRA Category 1 Credit™
  • 12.00 Non-Physician Participation
Course opens: 
01/13/2023
Course expires: 
04/18/2026
Event starts: 
01/01/2023 - 6:00am EST
Event ends: 
04/18/2023 - 11:59pm EDT
Rating: 
0

Tuesday, January 17th, 2023

6:00-6:10pm       Welcome and Introductions                                                                   Sennett Kim

6:10-6:20pm       Conflict of Interest Disclosures and Panel Responsibilities               Sennett Kim

6:20-8:45pm       OHSU Evidence Overview                                                                       Dr. Chou

8:45-9:00pm       Questions/Comments

 

Tuesday, March 21st, 2023

10:00-10:15am                 Introduction to review of Statement Development            Dr. Morgan, MD

10:15am-12:45pm            Guideline Statement Development                                       Panel

12:45-1:00pm                    Questions/Comments

 

Tuesday, April 11th, 2023

6:00-8:45pm       Continue Guideline Statement Development                                      Panel

8:45-9:00pm       Questions/Comments and Next Steps

 

Tuesday, April 18th, 2023

6:00-8:45pm       Continue working on remaining statements                                       Panel

8:45-9:00pm       Questions/Comments and Supporting Text assignments                 Panel

 

*All Eastern Time

Guideline Panel Disclosures

NameCompany NameRelationship TypeFinancialEnd Date
Boorjian, Stephen A.SUO-CTC Organized Clinical Trial Sponsored by FKDScientific Study or TrialNoCurrent
Boorjian, Stephen A.FerringConsultant or AdvisorYesCurrent
Boorjian, Stephen A.ArTaraConsultant or AdvisorYesCurrent
Boorjian, Stephen A.FerGeneConsultant or AdvisorYesCurrent
Boorjian, Stephen A.ProkariumConsultant or AdvisorYesCurrent
Buyyounouski, Mark K.Wolters KluwerHealth PublishingYesCurrent
Buyyounouski, Mark K.ElsevierHealth PublishingYesCurrent
Buyyounouski, Mark K.VarianOther-Departmental Research FundingYes06/30/2021
Chapin, Brian FrancisJansen and JansenConsultant or AdvisorNoCurrent
Chapin, Brian FrancisBlue Earth DiagnosticsScientific Study or TrialYesCurrent
Chapin, Brian FrancisRegeneronScientific Study or TrialNoCurrent
Chapin, Brian FrancisMerckConsultant or AdvisorNoCurrent
Chapin, Brian FrancisPfizerConsultant or AdvisorNoCurrent
Chapin, Brian FrancisJohnson and JohnsonConsultant or AdvisorYesCurrent
Chen, David Y. T.Pfizer, IncInvestment InterestNoCurrent
Chen, David Y. T.Pfizer, IncInvestment InterestNoCurrent
Chen, Ronald C.AstellasConsultant or Advisor (Family)YesCurrent
Chen, Ronald C.JanssenConsultant or AdvisorYesCurrent
Cheng, HeatherClovisScientific Study or TrialNoCurrent
Cheng, HeatherJanssenScientific Study or TrialNoCurrent
Cheng, HeatherMedivationScientific Study or TrialNoCurrent
Cheng, HeatherColor FoundationScientific Study or TrialNoCurrent
Cheng, HeatherSanofiScientific Study or TrialNoCurrent
Cheng, HeatherAstra ZenecaConsultant or AdvisorNoCurrent
Cheng, HeatherPhosplatinScientific Study or TrialNoCurrent
Feng, Felix YCJanssenConsultant or AdvisorYesCurrent
Feng, Felix YCPFS GenomicsConsultant or AdvisorNo04/14/2021
Feng, Felix YCVarianConsultant or Advisor (Family)Yes02/17/2022
Feng, Felix YCMyovantConsultant or AdvisorYes04/30/2021
Feng, Felix YCRoivantConsultant or AdvisorYes03/31/2021
Feng, Felix YCSerimmuneOther-Scientific advisor and I also own stock optionsYesCurrent
Feng, Felix YCBristol Meyers Squibb (formerly Celgene)Consultant or AdvisorYesCurrent
Feng, Felix YCExact SciencesConsultant or AdvisorYesCurrent
Feng, Felix YCArteraConsultant or AdvisorYesCurrent
Feng, Felix YCBayerConsultant or AdvisorYes03/31/2022
Feng, Felix YCFoundation MedicineConsultant or AdvisorYes02/28/2022
Feng, Felix YCTempus Labs, Inc.Consultant or AdvisorYes11/19/2022
Jacene, HeatherAdvanced Accelerator ApplicationsConsultant or AdvisorYesCurrent
Jacene, HeatherBlue Earth DiagnosticsConsultant or AdvisorYes06/21/2021
Jacene, HeatherGE HealthcareOther-Sponsored DinnerYes11/01/2021
Jacene, HeatherGTx, IncScientific Study or TrialYesCurrent
Jacene, HeatherSiemens HealthcareScientific Study or TrialYesCurrent
Jacene, HeatherSociety of Nuclear Medicine and Molecular ImagingOther-Committee Service Non-voting Board MemberNoCurrent
Jacene, HeatherAmerican Journal of RadiologyHealth PublishingYesCurrent
Jacene, HeatherSpectrum DynamicsConsultant or AdvisorYesCurrent
Jacene, HeatherTelixScientific Study or TrialYesCurrent
Jacene, HeatherUrotodayHealth PublishingYes05/23/2022
Jacene, HeatherSociety of Nuclear Medicine and Molecular ImagingOther-Voting memberNoCurrent
Kamran, Sophia CSanofi GenzymeEmployee (Family)YesCurrent
Kamran, Sophia CProstate Cancer FoundationScientific Study or TrialYesCurrent
Kamran, Sophia CASTROLeadership PositionNoCurrent
Kamran, Sophia CASCO GU SymposiumLeadership PositionNoCurrent
Kamran, Sophia CAmerican Board of RadiologyLeadership PositionNoCurrent
Luckenbaugh, Amy N.UroGenMeeting Participant or LecturerYesCurrent
Morgan, Todd MatthewMDxHealthScientific Study or TrialYes02/24/2022
Morgan, Todd MatthewMyriad GeneticsScientific Study or TrialYes12/31/2021
Morgan, Todd MatthewBlue EarthConsultant or AdvisorYes02/28/2021
Morgan, Todd MatthewStratify GenomicsConsultant or AdvisorYes03/03/2021
Morgan, Todd MatthewMyovant BiosciencesConsultant or AdvisorYes11/01/2021
Morgan, Todd MatthewTempusConsultant or AdvisorYes12/17/2021
Nathanson, BenAnCan FoundationOther-Unpaid volunteer moderator in online peer-support meetingsNoCurrent
Nyame, Yaw A.Ortho-Clinical DiagnosticsConsultant or AdvisorYesCurrent
Posadas, Edwin MelencioBayerMeeting Participant or LecturerYesCurrent
Posadas, Edwin MelencioPfizerScientific Study or TrialNoCurrent
Posadas, Edwin MelenciomovantMeeting Participant or LecturerYesCurrent
Tran, Phuoc TJanssen-Taris BiomedicalConsultant or AdvisorYesCurrent
Tran, Phuoc TRefleXion MedicalConsultant or AdvisorYesCurrent
Tran, Phuoc TNatsar PharmaceuticalsIntellectual PropertyYesCurrent

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 12.0 AMA PRA Category 1 Credit™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 12.00 AMA PRA Category 1 Credit™
  • 12.00 Non-Physician Participation
Please login or register to take this course.

Registration for this activity is limited to Salvage Therapy for Prostate Cancer Guideline Panel Members only.